Skip to main content
 

Mediwhale

Mediwhale

Mediwhale is an innovative retina-based AI company that autonomously assesses cardiovascular disease risk. With a simple eye scan using fundus cameras, the company’s AI algorithm analyzes the blood vessels in the retinal images and generates a future cardiovascular disease risk with comparable performance to a heart CT scan within a minute, providing a safe, affordable, and accessible solution at the point of care. Mediwhale also expands the coverage from cardiovascular disease to renal and metabolic diseases.

More News

  • PharmaSmart Joins American Heart Association Innovators’ Network to Advance Evidence-Based Chronic Disease Screening and Community Health Technology & Innovation

  • AI Agents: From Chatbots to Patient Prescribing

  • How AI tools can enable more proactive care